CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and
safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
Celtaxsys, Inc.
Collaborators:
Celtaxsys Aus Pty Limited Clinical Network Services (CNS) Pty Ltd